Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-550-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$141.10 million
Profitability
Miscellaneous
Employees39
OptionableOptionable
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its earnings results on Thursday, November, 8th. The biotechnology company reported $1.32 EPS for the quarter, beating analysts' consensus estimates of $1.03 by $0.29. The biotechnology company earned $45.66 million during the quarter, compared to analysts' expectations of $41.99 million. Ligand Pharmaceuticals had a return on equity of 26.17% and a net margin of 73.78%. Ligand Pharmaceuticals's revenue for the quarter was up 36.8% on a year-over-year basis. During the same period last year, the business posted $0.69 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
How can I listen to Ligand Pharmaceuticals' earnings call?
Ligand Pharmaceuticals will be holding an earnings conference call on Thursday, February 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8335914752.
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals issued an update on its FY 2019 earnings guidance on Tuesday, December, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $212 million.Ligand Pharmaceuticals also updated its FY 2018 guidance to $6.63 EPS.
What price target have analysts set for LGND?
6 analysts have issued 1-year target prices for Ligand Pharmaceuticals' shares. Their forecasts range from $195.00 to $300.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $256.6667 in the next twelve months. This suggests a possible upside of 117.7% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand's Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, Ligand’s internal pipeline has several candidates in development that could generate future licensing opportunities. Ligand is acquiring other technology platforms to reduce dependence on Captisol formulation. Shares of Ligand have significantly outperformed the industry in the past year. The company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Both the drugs have shown encouraging growth with blockbuster potential. However, any setback related to either of these products could have a substantial impact." (1/3/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $281 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 178 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (11/5/2018)
Has Ligand Pharmaceuticals been receiving favorable news coverage?
News stories about LGND stock have been trending somewhat negative on Monday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG) and Alkermes (ALKS).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 49)
- Mr. Matthew W. Foehr, Pres & COO (Age 46)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Woodstock Corp (0.33%), Summit Creek Advisors LLC (0.22%), Retirement Systems of Alabama (0.13%), Boston Advisors LLC (0.03%), Louisiana State Employees Retirement System (0.03%) and Navellier & Associates Inc (0.02%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including Navellier & Associates Inc and Louisiana State Employees Retirement System. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Summit Creek Advisors LLC, Woodstock Corp, Fox Run Management L.L.C., Campbell Newman Asset Management Inc., Boston Advisors LLC, Virtu Financial LLC and First Hawaiian Bank. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $117.90.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $2.51 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
